Pozen discontinues MT 100 development

Following Thursday's review by the FDA's Peripheral and Central Nervous System Drugs Advisory Committee, POZN said it will discontinue development of migraine compound MT 100 in the U.S. The panel said that the potential risks of tardive dyskinesia (TD) associated with metoclopramide would outweigh the benefits of the combination (see BioCentury Extra, Thursday Aug. 4, 2005). FDA issued a not approvable letter for MT 100 to treat migraine in 2004. ...